This site is intended for healthcare professionals
Drug News

CC-486 has NDA accepted by FDA for maintenance treatment of adult patients in remission with acute myeloid leukemia.- BMS

Read time: 1 mins
Last updated:28th Jun 2021
Published:2nd May 2020
Condition: Acute Myelogeous Leukemia (AML)
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest